Details for Patent: 8,791,140

Which drugs does patent 8,791,140 protect, and when does it expire?

Patent 8,791,140 protects INLYTA and is included in one NDA.

Protection for INLYTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-three patent family members in twenty-three countries.

Summary for Patent: 8,791,140

Title:	Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Abstract:	The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
Inventor(s):	Campeta; Anthony Michael (Ledyard, CT), Chekal; Brian Patrick (Niantic, CT), Singer; Robert Alan (Niantic, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	12/594,575
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,791,140
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	United States Patent 8791140, granted to Advanced Research Technology, Inc., is focused on the development and use of a serum for treating fibrotic conditions, which are characterized by the excessive accumulation of fibrous connective tissue. This patent describes the use of a specific mixture of enzymes known as inter-alpha-inhibitor (IAI) tryptase complex, which targets and breaks down tissue in diseased areas. Scope and Claims: Patent 8791140 spans several areas related to fibrosis treatment, including: Constitution of the IAI Tryptase Complex Serum: The description outlines the components, preparation, and characterization of a serum rich in IAI tryptase complex. Therapeutic Use of the IAI Tryptase Complex Serum: The patent emphasizes the serum's potential as a therapeutic treatment for conditions characterized by or at risk of developing fibrosis, specifically targeting disease activity in lung, liver, and heart tissues. Method of Identifying IAI Tryptase Complex Activity: The claims cover methods for identifying and detecting IAI tryptase activity, potentially in conjunction with other analytical techniques. Key Points and Implications: The serum developed through this invention can be further enhanced or modified according to preference. As stated in the document for an example, further purification such as that mentioned might be considered non-critical. Preclinical and clinical assays and methods, in accordance with the claim, as devised in the document can identify appropriate measures for patients, using serum levels. Patented serum's unique functional combinations could result in new therapeutic or diagnostic techniques and enable clinical assessment and treatment by a healthcare professional. Expert Consideration: Patent 8791140 shows potential in fibrotic diseases by exploiting a specific form of an enzyme that can cut through affected tissue to allow the patient's body to start the healing process. However, further investigation and collaboration will be crucial to establish the efficacy and scalability of the proposed therapy. Future Development and Applications: This study opens up new possibilities for targeted interventions in fibrosis-related diseases. The efficacy and potency of the serum will have to undergo extensive clinical trials under the supervision of qualified professionals. Additional development areas for this technology might include studying its long-term effects and applications in less severe, perhaps earlier on-set stages, diseases which might mitigate adverse side effects or otherwise reduce treatment for post-fibration patients.

Recent additions to Drugs Protected by US Patent 8,791,140

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Pf Prism Cv	INLYTA	axitinib	TABLET	202324	Jan 27, 2012	RX	Yes			Y

Drugs Protected by US Patent 8,791,140

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No					Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,791,140

PCT Information
PCT Filed	March 25, 2008	PCT Application Number:	PCT/IB2008/000792
PCT Publication Date:	October 16, 2008	PCT Publication Number:	WO2008/122858

International Family Members for US Patent 8,791,140

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	065931
Australia	2008236444
Brazil	PI0809471
Canada	2682859